Douglas L. Mann mainly investigates Internal medicine, Heart failure, Endocrinology, Tumor necrosis factor alpha and Heart disease. He interconnects Placebo and Cardiology in the investigation of issues within Internal medicine. His Heart failure research is multidisciplinary, relying on both Randomized controlled trial, Surgery and Immunology.
His Endocrinology research is multidisciplinary, incorporating elements of Proinflammatory cytokine and Cytokine. His studies in Tumor necrosis factor alpha integrate themes in fields like Homeostasis, Interleukin 6, Myocyte, Cachexia and In vivo. The various areas that Douglas L. Mann examines in his Heart disease study include Cornerstone, Hemodynamics, Cardiac output and Survival analysis.
His primary areas of investigation include Internal medicine, Heart failure, Cardiology, Ejection fraction and Tumor necrosis factor alpha. His Internal medicine research incorporates elements of Endocrinology and Surgery. His work carried out in the field of Heart failure brings together such families of science as Heart disease, Immunology, Clinical trial and Intensive care medicine.
His work in Cardiology tackles topics such as Stroke which are related to areas like Sinus rhythm. Douglas L. Mann has researched Ejection fraction in several fields, including Placebo, Randomized controlled trial, Blood pressure and Hazard ratio. His research in Tumor necrosis factor alpha intersects with topics in Cancer research, Cytokine, Pathogenesis, Receptor and Proinflammatory cytokine.
Douglas L. Mann mostly deals with Heart failure, Internal medicine, Cardiology, Ejection fraction and Ambulatory. He combines subjects such as Clinical trial, Inflammation, Quality of life, Intensive care medicine and Cohort with his study of Heart failure. Much of his study explores Internal medicine relationship to Placebo.
His Cardiology research integrates issues from Randomized controlled trial and Proportional hazards model. His Ejection fraction research includes themes of Platelet aggregation inhibitor, Aspirin, Warfarin, Heart transplantation and Confidence interval. He interconnects Ventricular assist device, Quality of life, Emergency medicine, Circulatory system and Transplantation in the investigation of issues within Ambulatory.
His primary areas of study are Heart failure, Internal medicine, Ejection fraction, Cardiology and Cohort. His Heart failure research is multidisciplinary, incorporating elements of Endocrinology, Quality of life, Adverse outcomes and Apolipoprotein B. As part of his studies on Internal medicine, Douglas L. Mann often connects relevant areas like Physical interaction.
His research integrates issues of Clinical course, Disease management, Immunity and Heart transplantation in his study of Ejection fraction. His biological study spans a wide range of topics, including Aspirin and Randomized controlled trial. His work in Cohort covers topics such as Ambulatory which are related to areas like Emergency medicine and Ventricular assist device.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
A. Hjalmarson;S. Goldstein;B. Fagerberg;H. Wedel.
The Lancet (1999)
The Seattle Heart Failure Model Prediction of Survival in Heart Failure
Wayne C. Levy;Dariush Mozaffarian;David T. Linker;Santosh C. Sutradhar.
Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine
Douglas L. Mann;Douglas P. Zipes;Peter Libby;Robert O. Bonow.
Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)
Guillermo Torre-Amione;Samir Kapadia;Claude Benedict;Hakan Oral.
Journal of the American College of Cardiology (1996)
Cytokines and Cytokine Receptors in Advanced Heart Failure An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST)
Anita Deswal;Nancy J. Petersen;Arthur M. Feldman;James B. Young.
Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart
Guillermo Torre-Amione;Samir Kapadia;Joseph Lee;Jean Bernard Durand.
Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
Douglas L. Mann;John J.V. McMurray;Milton Packer;Karl Swedberg.
Inflammatory Mediators and the Failing Heart Past, Present, and the Foreseeable Future
Douglas L. Mann.
Circulation Research (2002)
Pathophysiologically relevant concentrations of tumor necrosis factor- α promote progressive left ventricular dysfunction and remodeling in rats
Biykem Bozkurt;Scott B. Kribbs;Fred J. Clubb;Lloyd H. Michael.
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
Margaret M. Redfield;Horng H. Chen;Barry A. Borlaug;Marc J. Semigran.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: